Sopharma has completed the initial stage of a strategic pharmaceutical portfolio acquisition
November 2024 — As part of Sopharma’s growth strategy to expand its regional market footprint, the company has recently completed the first stage of a transaction to acquire a large pharmaceutical product portfolio, including both consumer healthcare and prescription products.
Sopharma is a leading producer and distributor of pharmaceutical products in Europe and the Commonwealth of Independent States (CIS), operating with a vertically integrated business model that spans the entire value chain. The company is present in over 30 countries, with a combined revenue of €1 billion.
The pharmaceutical product portfolio acquired includes both consumer healthcare (CHC) and prescription products across diverse therapeutic areas such as sex hormones and modulators of the genital system, urologicals and antivirals for systemic use. Comprising 68 marketing authorizations, the portfolio features 14 well-known brands across 10 of Sopharma’s key markets. The transaction will be executed in stages, with the initial payment of €40 million secured by own funds and bank financing.
The seller is a European pharmaceutical company, which is developing, manufacturing and marketing a wide range of generic and over-the-counter (OTC) products.
Our role in the transaction
Oaklins’ team in Bulgaria advised Sopharma throughout the acquisition process, including transaction positioning and structuring, deal negotiations and execution.
Contacter l'équipe de la transaction
Transactions connexes
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
En apprendre plusLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
En apprendre plusRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
En apprendre plus